Top

European Journal of Nutrition

Published in:

01-09-2020 | Insulins | Original Contribution

The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial

Authors: Zahra Yari, Mina Movahedian, Hossein Imani, Seyed Moayed Alavian, Mehdi Hedayati, Azita Hekmatdoost

Published in: European Journal of Nutrition | Issue 6/2020

Abstract

Purpose

Hesperidin as an antioxidant flavonoid exerts anti-adipogenic, anti-inflammatory, anti-oxidant and anti-hypercholesterolemic effects. Besides, the increasing prevalence of metabolic syndrome (MetS) and its allied complications, on the one hand, and the willingness of individuals to use natural products for curing their diseases, on the other hand, led to the design of this study to evaluate the efficacy of hesperidin in normalizing the metabolic abnormalities in patients with MetS.

Methods

In this clinical trial with a parallel-group design, 49 patients with MetS received either 500-mg hesperidin or placebo, twice daily, for 12 weeks. Number of participants with treated MetS was considered as a primary end point. Anthropometric parameters, dietary intake, physical activity, lipid profile, glucose homeostasis parameter, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP) were assessed at the beginning and at the end of the study. This trial is registered at clinicaltrials.gov as NCT03734874.

Results

Compared with the placebo group, hesperidin decreased fasting glucose level (− 6.07 vs. − 13.32 mg/dL, P = 0.043), triglyceride (− 8.83 vs. − 49.09 mg/dL, P = 0.049), systolic blood pressure (− 0.58 vs. − 2.68 mmHg, P = 0.048) and TNF-α (− 1.29 vs. − 4.44 pg/mL, P = 0.009). Based on the within-group analysis, hesperidin led to significant decrease in serum levels of glucose, insulin, triglyceride, total cholesterol, low density lipoprotein cholesterol, TNF-α and hs-CRP, while in control group only glucose and insulin significantly decreased.

Conclusions

The results indicate that hesperidin supplementation can improve metabolic abnormalities and inflammatory status in patients with MetS.

Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH (2008) The metabolic syndrome. Endocr Rev 29(7):777–822PubMedPubMedCentral

Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28(7):1769–1778PubMed

Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28(1):27–38PubMed

Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, Torres M, Hernandez R, Wilson E (2009) Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 8(1):52PubMedPubMedCentral

Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, Borghi C (2018) Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella heart study. Sci Rep 8(1):11529PubMedPubMedCentral

Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164(10):1066–1076PubMed

Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M (2001) Central role of the adipocyte in the metabolic syndrome. J Investig Med 49(1):119–126PubMed

Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard J, Hunninghake DB, Illingworth DR, Luepker RV, McBride P (2002) Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 106(25):3143–3421

National CEPN (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25):3143

10.

Hanley AJ, Festa A, D’Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM (2004) Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53(7):1773–1781PubMed

11.

Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE (2004) Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 53(8):2087–2094PubMed

12.

Ferrannini E, Haffner S, Mitchell B, Stern M (1991) Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34(6):416–422PubMed

13.

Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles J (1989) Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Investig 83(4):1168–1173PubMed

14.

Reaven G (2004) The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33(2):283–303PubMed

15.

Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. The lancet 365(9468):1415–1428

16.

Ehteshami M, Shakerhosseini R, Sedaghat F, Hedayati M, Eini-Zinab H, Hekmatdoost A (2018) The effect of gluten free diet on components of metabolic syndrome: a randomized clinical trial. Asian Pac J Cancer Prev 19(10):2979–2984. https://doi.org/10.22034/apjcp.2018.19.10.2979 CrossRefPubMedPubMedCentral

17.

Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R, Poustchi H (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr 112(3):438–445. https://doi.org/10.1017/s0007114514000919 CrossRefPubMed

18.

Ghorbani Z, Hekmatdoost A, Mirmiran P (2014) Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Phytother Res 12(4):e18081. https://doi.org/10.5812/ijem.18081 CrossRef

19.

Hekmatdoost A, Mirmiran P, Hosseini-Esfahani F, Azizi F (2011) Dietary fatty acid composition and metabolic syndrome in Tehranian adults. Nutrition 27(10):1002–1007. https://doi.org/10.1016/j.nut.2010.11.004 CrossRefPubMed

20.

Mirmiran P, Hekmatdoost A, Azizi F (2007) Metabolic syndrome is associated with adherence to an unhealthy diet. Diabetes Care 30(9):e93. https://doi.org/10.2337/dc06-1928 CrossRefPubMed

21.

Yari Z, Rahimlou M, Poustchi H, Hekmatdoost A (2016) Flaxseed supplementation in metabolic syndrome management: a pilot randomized, open-labeled, controlled Study. Phytother Res 30(8):1339–1344. https://doi.org/10.1002/ptr.5635 CrossRefPubMed

22.

Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mannina C, Castellino G, Chianetta R, Banach M, Cicero AF, Lippi G (2018) Natural approaches in metabolic syndrome management. Arch Med Sci 14(2):422PubMed

23.

Cicero AFG, Colletti A, Fogacci F, Bove M, Rosticci M, Borghi C (2017) Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial. High Blood Press Cardiovasc Prev 24(1):13–18PubMed

24.

Amiot M, Riva C, Vinet A (2016) Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev 17(7):573–586PubMed

25.

Cicero AF, Caliceti C, Fogacci F, Giovannini M, Calabria D, Colletti A, Veronesi M, Roda A, Borghi C (2017) Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study. Mol Nutr Food Res 61(11):1700373

26.

Giglio RV, Patti AM, Cicero AF, Lippi G, Rizzo M, Toth PP, Banach M (2018) Polyphenols: potential use in the prevention and treatment of cardiovascular diseases. Curr Pharm Des 24(2):239–258PubMed

27.

Manach C, Williamson G, Morand C, Scalbert A, Rémésy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1):230S–242SPubMed

28.

Haidari F, Heybar H, Jalali M, Ahmadi Engali K, Helli B, Shirbeigi E (2015) Hesperidin supplementation modulates inflammatory responses following myocardial infarction. J Am Coll Nutr 34(3):205–211PubMed

29.

Mosqueda-Solís A, Sánchez J, Reynés B, Palou M, Portillo MP, Palou A, Picó C (2018) Hesperidin and capsaicin, but not the combination, prevent hepatic steatosis and other metabolic syndrome-related alterations in western diet-fed rats. Sci Rep 8(1):15100PubMedPubMedCentral

30.

Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K (2018) Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial. Phytother Res 32(6):1073–1079. https://doi.org/10.1002/ptr.6046 CrossRefPubMed

31.

Miwa Y, Mitsuzumi H, Sunayama T, Yamada M, Okada K, Kubota M, Chaen H, Mishima Y, Kibata M (2005) Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol 51(6):460–470PubMed

32.

Demonty I, Lin Y, Zebregs YE, Vermeer MA, van der Knaap HC, Jakel M, Trautwein EA (2010) The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr 140(9):1615–1620. https://doi.org/10.3945/jn.110.124735 CrossRefPubMed

33.

NHLBI Obesity Education Initiative (2000) The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Obesity, BMI, waist circumference, freatment overweight ; NHLBI obesity education initiative. National Institutes of Health

34.

Mohammadi M, Eghtesadi S, Vafa M, Heydari I, Salehi M, Shirbeigi E, Mohammadi H (2016) The effect of hesperidin supplementation on indices of glucose and lipid, insulin levels and insulin resistance in patients with type 2 diabetes: a randomized double-blind clinical trial. Razi J Med Sci 23(143):71–80

35.

Willett W (2012) Nutritional epidemiology, vol 40. Oxford University Press, Oxford

36.

Klishadi R, Khosravi A, Famouri F, Sadeghi M, Shirani S (2001) Assessment of physical activity of adolescents in Isfahan. J Shahrekord Univ Med Sci 3(2):27–33

37.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMed

38.

Jung UJ, Lee M-K, Park YB, Kang MA, Choi M-S (2006) Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol 38(7):1134–1145PubMed

39.

Jung UJ, Lee M-K, Jeong K-S, Choi M-S (2004) The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr 134(10):2499–2503PubMed

40.

Ahmed OM, Mahmoud AM, Abdel-Moneim A, Ashour MB (2012) Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats. Diabetol Croat 41(2):53–67

41.

Mohammadi M, Ramezani-Jolfaie N, Lorzadeh E, Khoshbakht Y, Salehi-Abargouei A (2019) Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res 33(3):534–545PubMed

42.

Gorinstein S, Vargas OJM, Jaramillo NO, Salas IA, Ayala ALM, Arancibia-Avila P, Toledo F, Katrich E, Trakhtenberg S (2007) The total polyphenols and the antioxidant potentials of some selected cereals and pseudocereals. Eur Food Res Technol 225(3–4):321–328

43.

Monforte M, Trovato A, Kirjavainen S, Forestieri A, Galati E, Lo RC (1995) Biological effects of hesperidin, a Citrus flavonoid (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco (SocietÃ chimica italiana: 1989) 50(9):595–599

44.

Akiyama S, Katsumata S-i, Suzuki K, Nakaya Y, Ishimi Y, Uehara M (2009) Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci Biotechnol Biochem 73(12):2779–2782PubMed

45.

Gorinstein S, Leontowicz H, Leontowicz M, Krzeminski R, Gralak M, Jastrzebski Z, Park YS, Jung ST, Kang SG, Trakhtenberg S (2007) Effect of hesperidin and naringin on the plasma lipid profile and plasma antioxidant activity in rats fed a cholesterol-containing diet. J Sci Food Agric 87(7):1257–1262

46.

Lorzadeh E, Ramezani-Jolfaie N, Mohammadi M, Khoshbakht Y, Salehi-Abargouei A (2019) The effect of hesperidin supplementation on inflammatory markers in human adults: a systematic review and meta-analysis of randomized controlled clinical trials. Chem Biol Interact 307:8–15PubMed

47.

Jain M, Parmar HS (2011) Evaluation of antioxidative and anti-inflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation. Inflamm Res 60(5):483–491PubMed

48.

Kuntić V, Brborić J, Holclajtner-Antunović I, Uskoković-Marković S (2014) Evaluating the bioactive effects of flavonoid hesperidin: a new literature data survey. Vojnosanit Pregl 71(1):60–65PubMed

49.

Rizza S, Muniyappa R, Iantorno M, Kim J-a, Chen H, Pullikotil P, Senese N, Tesauro M, Lauro D, Cardillo C (2011) Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 96(5):E782–E792PubMedPubMedCentral

50.

Choi I-Y, Kim S-J, Jeong H-J, Park S-H, Song Y-S, Lee J-H, Kang T-H, Park J-H, Hwang G-S, Lee E-J (2007) Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol Cell Biochem 305(1–2):153–161PubMed

51.

Lin HY, Shen SC, Chen YC (2005) Anti-inflammatory effect of heme oxygenase 1: glycosylation and nitric oxide inhibition in macrophages. J Cell Physiol 202(2):579–590PubMed

52.

Pinho-Ribeiro FA, Hohmann MS, Borghi SM, Zarpelon AC, Guazelli CF, Manchope MF, Casagrande R, Verri WA Jr (2015) Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chem Biol Interact 228:88–99PubMed

53.

Vabeiryureilai M, Lalrinzuali K, Jagetia G (2015) Determination of anti-inflammatory and analgesic activities of a citrus bioflavanoid, hesperidin in mice. Immunochem Immunopathol Open Access 1(107):2

54.

Tirkey N, Pilkhwal S, Kuhad A, Chopra K (2005) Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol 5(1):2PubMedPubMedCentral

55.

Calderone V, Chericoni S, Martinelli C, Testai L, Nardi A, Morelli I, Breschi MC, Martinotti E (2004) Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels. Naunyn Schmiedeberg’s Arch Pharmacol 370(4):290–298

56.

Mira L, Tereza Fernandez M, Santos M, Rocha R, Helena Florêncio M, Jennings KR (2002) Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radical Res 36(11):1199–1208

57.

Vaziri ND, Rodríguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Rev Nephrol 2(10):582

58.

Ikemura M, Sasaki Y, Giddings JC, Yamamoto J (2012) Preventive effects of hesperidin, glucosyl hesperidin and naringin on hypertension and cerebral thrombosis in stroke-prone spontaneously hypertensive rats. Phytother Res 26(9):1272–1277PubMed

59.

Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, Iwasaki Y, Kondo Y (2003) Glucosyl hesperidin improves serum cholesterol composition and inhibits hypertrophy in vasculature. J Nutr Sci Vitaminol 49(6):447–450PubMed

60.

Dobiaš L, Petrová M, Vojtko R, Kristová V (2016) Long-term treatment with hesperidin improves endothelium-dependent vasodilation in femoral artery of spontaneously hypertensive rats: the involvement of NO-synthase and Kv channels. Phytother Res 30(10):1665–1671PubMed

61.

Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, Iwasaki Y, Kondo Y (2002) Effects of long-term administration of hesperidin and glucosyl hesperidin to spontaneously hypertensive rats. J Nutr Sci Vitaminol 48(5):420–422PubMed

62.

Takumi H, Nakamura H, Simizu T, Harada R, Kometani T, Nadamoto T, Mukai R, Murota K, Kawai Y, Terao J (2012) Bioavailability of orally administered water-dispersible hesperetin and its effect on peripheral vasodilatation in human subjects: implication of endothelial functions of plasma conjugated metabolites. Food Funct 3(4):389–398PubMed

63.

Yamamoto M, Jokura H, Hashizume K, Ominami H, Shibuya Y, Suzuki A, Hase T, Shimotoyodome A (2013) Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3′-O-glucuronide, exerts hypotensive, vasodilatory, and anti-inflammatory activities. Food Funct 4(9):1346–1351PubMed

Title: The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial
Authors: Zahra Yari
Mina Movahedian
Hossein Imani
Seyed Moayed Alavian
Mehdi Hedayati
Azita Hekmatdoost
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Insulins
Published in: European Journal of Nutrition / Issue 6/2020
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-019-02105-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2020

Reply to the comments by Vorland et al. on our paper: “low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12-week, randomized, parallel-design intervention study”

NAD+ precursor increases aerobic performance in mice

Mineral and vitamin intake of infants and young children: the Nutri-Bébé 2013 survey

Is there a soft drink vs. alcohol seesaw? A cross-sectional analysis of dietary data in the Australian Health Survey 2011–12

Lower carbohydrate and higher fat intakes are associated with higher hemoglobin A1c: findings from the UK National Diet and Nutrition Survey 2008–2016

Co-ingestion of whey protein hydrolysate with milk minerals rich in calcium potently stimulates glucagon-like peptide-1 secretion: an RCT in healthy adults

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page